Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Anal cancer, Bladder cancer, Bowel (colorectal) cancer, Breast cancer, Head and neck cancers, Kidney cancer, Laryngeal cancer, Liver cancer, Lung cancer, Mouth and oropharyngeal cancer, Non small cell lung cancer (NSCLC), Ovarian cancer, Pancreatic cancer, Pharyngeal cancer, Prostate cancer, Renal cell cancer, Stomach cancer
Closed
Phase 1
This study is looking at a drug called INCB106385 by itself or with another drug called retifanlimab (INCMGA00012) for some solid cancers. It is open to people with cancer that has spread to another part of the body or the nearby tissue (advanced cancer).
A is any cancer apart from blood cancers such as leukaemia and lymphoma.
Recruitment start: 13 June 2022
Recruitment end: 18 April 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Rebecca Kristeleit
Incyte Corporation
Last reviewed: 17 May 2023
CRUK internal database number: 18043